Form 4: Lilly Endowment Sells $81.5M in Eli Lilly Stock

Lilly Endowment Inc., a 10% owner of Eli Lilly & Co., reported selling 106,626 shares of common stock for approximately $81.5 million on September 18, 2025.

Summary

• Lilly Endowment Inc. reported the sale of 106,626 shares of Eli Lilly & Co. common stock.
• The transactions occurred on September 18, 2025, across five separate sales.
• The total value of the shares sold is approximately $81,548,000, based on weighted average prices ranging from $763.292 to $767.065 per share.
• Following these transactions, Lilly Endowment Inc. beneficially owns 95,630,352 shares of Eli Lilly & Co. common stock.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 4

Explanation: A significant sale by a 10% owner, even if pre-planned, can be interpreted cautiously by the market as it represents a reduction in a major stakeholder's commitment, potentially signaling a less optimistic outlook or a strategic shift by the seller.

Positives

• Lilly Endowment Inc. realized significant capital from the sale of shares at high market prices, indicating a successful investment for the reporting person.
• The company's stock traded at robust prices, ranging from $763.00 to $767.5958 per share, during the period of these sales.

Negatives

• A 10% owner, Lilly Endowment Inc., significantly reduced its stake in Eli Lilly & Co. by selling 106,626 shares, which could be perceived by the market as a lack of confidence or a strategic reallocation away from the issuer.
• The substantial value of shares sold, approximately $81.5 million, represents a significant divestment by a major shareholder.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• Diane M. Stenson, Vice President & Treasurer, signed on behalf of Lilly Endowment Inc.

Industry Context

This filing reports an insider transaction and does not provide direct information on broader industry trends or competitive landscape. However, significant insider sales by major shareholders in the pharmaceutical sector can sometimes lead to market speculation regarding the company's near-term prospects or the shareholder's portfolio rebalancing strategy.

Related Party Transactions

• Lilly Endowment Inc., identified as a 10% owner of Eli Lilly & Co., engaged in sales of common stock. Transactions involving a 10% owner are considered related party transactions.

Stakeholder Impact

• Shareholders may view the significant sale by a 10% owner as a potential negative signal, which could influence market sentiment and the company's stock price.
• Lilly Endowment Inc. has successfully monetized a portion of its investment, realizing substantial capital gains.

Key Dates

Recommendation

The substantial sale of shares by Lilly Endowment Inc., a 10% owner, warrants a cautious 'hold' recommendation. While the sale was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled, such a significant divestment by a major stakeholder can be interpreted by the market as a signal of reduced confidence or a strategic portfolio rebalancing. Investors should monitor future developments and consider this transaction in the context of broader market and company-specific news before making significant investment decisions.

Keywords

Eli Lilly & Co., LLY, Lilly Endowment Inc., Insider Sale, Form 4, SEC Filing, Stock Transaction, 10b5-1 Plan, Pharmaceuticals, Biotechnology